News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
NOXXON Pharma AG Announces Appointment of Lawrence E. Posner to Its Board of Directors
July 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the appointment of Lawrence E. Posner, MD, to its Board of Directors.
Twitter
LinkedIn
Facebook
Email
Print
People
Europe
MORE ON THIS TOPIC
Layoff Tracker
Bicycle Downsizes by 30% After Deprioritizing Lead Program
March 18, 2026
·
37 min read
·
BioSpace Editorial Staff
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
March 17, 2026
·
2 min read
·
Tristan Manalac
Government
As Midterms Loom, White House Cracks Down on RFK Jr.’s Vaccine Policies—but MAHA Resists
March 16, 2026
·
4 min read
·
Tristan Manalac
Earnings
Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings
March 13, 2026
·
5 min read
·
Annalee Armstrong
